BioCardia’s (BCDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDAFree Report) in a report issued on Wednesday, Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock.

BioCardia Stock Performance

NASDAQ BCDA opened at $4.62 on Wednesday. BioCardia has a one year low of $4.35 and a one year high of $43.80. The company’s 50 day moving average price is $5.69 and its 200 day moving average price is $7.41. The firm has a market capitalization of $126.13 million, a price-to-earnings ratio of -9.83 and a beta of 1.47.

BioCardia (NASDAQ:BCDAGet Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) earnings per share (EPS) for the quarter. BioCardia had a negative net margin of 2,208.76% and a negative return on equity of 3,638.68%. The firm had revenue of $0.06 million during the quarter. During the same period last year, the business earned ($2.55) earnings per share. Sell-side analysts forecast that BioCardia will post -0.42 EPS for the current fiscal year.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

Featured Articles

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.